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Androgen deprivation therapy (ADT) is a frequent treatment
used in patients with prostate cancer (PCa). ADT can be used
as neoadjuvant therapy before radical prostatectomy to
decrease the rates of local recurrence and positive margins,
as primary treatment for PCa, and as adjuvant therapy after
radical prostatectomy, in a continuous or intermittent regimen
[1, 2]. ADT can be performed with different drugs, including
gonadotropin-releasing hormone (GnRH) agonists, GnRH
antagonists, antagonists of the androgen receptor, and 5α-
reductase inhibitors [1, 2]. ADT leads to depletion of
testosterone levels, inactivation of the androgen receptor, or
both (i.e. castration) [2]. As normal prostate cells as well as
PCa cells are initially dependent on testosterone for
replication and growth, many cancer cells will senesce in
response to the onset of the biochemical castration state [2].
In spite of castration, many patients will experience an
increase in PSA and ultimately will develop metastases (i.e.
androgen-independence or hormonal resistance) [1, 2].
In the current issue of the EJNMMI, Fuccio et al. report
their results concerning the effect of ADT on the uptake of
[11C]choline in 14 PCa patients who were scanned twice
with PET/CT [3]. Patients were initially scanned due to
biochemical failure after radical prostatectomy. Patients had
never taken antiandrogenic drugs at the time of the first
PET/CT scan. In 13 of the 14 patients the first [11C]choline
PET/CT scan was positive. After the first PET/CT scan, all
patients received ADT (GnRH agonists in 12 patients,
bicalutamide in 2 patients) for a minimum period of
6 months. The second [11C]choline PET/CT scan was
positive in only 5 of the 14 patients. All nine patients with
a negative PET/CT scan after ADT initially had a positive
PET/CT scan. [11C]choline uptake disappeared for skeletal
and extraskeletal lesions. In all these nine patients, PSA
after ADT either reverted to undetectable levels or showed a
substantial decrease in comparison to the baseline scan. The
patient with a negative initial scan showed a positive
second scan, representing a false-negative. The remain-
ing four patients showed some increase in PSA levels as
well as progression on the PET/CT scan indicating rapid
evolution to hormone resistance. The authors correctly
concluded that an inhibitory effect of ADT on [11C]
choline uptake occurred only in patients with hormone-
sensitive PCa [3].
To the best of our knowledge, DeGrado et al. were the
first to report an inhibitory effect of ADT on the uptake of
radiolabelled choline in vivo in their initial evaluation of
[18F]fluorocholine [4]. These authors described the case of
a 59-year-old man with untreated locally advanced PCa that
displayed [18F]fluorocholine uptake in the primary tumour
and in several skeletal metastases. The lesions were still
visible 2 months after ADT, but the intensity of uptake
decreased by more than 60% [4]. De Waele et al. reported a
similar case of a 57-year-old man with PCa at initial staging
who displayed focal [11C]choline uptake in the prostate and
in multiple iliac lymph nodes [5]. After 6 months of therapy
with leuprorelin and flutamide [11C]choline uptake was no
longer visible [5].
The study by Fuccio et al. [3] has the merit of having
addressed with a sufficient sample size a timely relevant
scientific question. Many studies with PET/CT and radio-
labelled choline have either provided insufficient informa-
tion about the ADT status of the patients or mixed
hormone-sensitive patients with hormone-resistant patients
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and failed to report separate results for the two subgroups
[6–10]. The results obtained by Fuccio et al. further extend
previous in vitro and in vivo studies [11–13]. Hara et al.
showed that androgen depletion reduces the uptake of
tritiated choline in androgen-dependent LNCaP cells but
not in androgen-independent PC-3 cells [11]. Similar results
have been reported by Emonds et al. in a paper also
published in the current issue of the EJNMMI [12]. These
authors reported that androgens induced a time-dependent
stimulation in [11C]choline uptake in androgen-sensitive
PC346C cells but had no effect in androgen-independent
PC-3 cells [12]. Giovacchini et al. assessed the effect of
neoadjuvant ADT in a small group of six patients treated
with the androgen receptor antagonist bicalutamide (median
treatment of 4 months) [13]. In the whole group, prostate
SUVmax after therapy was significantly reduced compared
to the baseline value, with a mean decrease of 45%.
Visually, the metabolically active area was smaller after
ADT than at baseline [13]. Several mechanisms could
account for the decrease in [11C]choline SUVmax after ADT,
including a reduction in prostate volume (i.e. partial volume
effect), atrophy of glandular cells with loss of the prostatic
metabolites choline, creatine and citrate, reduced proliferation
rate, downregulation of the expression of genes involved in
lipid metabolism, including the choline transporter or choline
kinase activity [13–18].
In summary, in vitro and in vivo studies provide strong
evidence that the uptake of radiolabelled choline will be
significantly reduced by ADT in patients with hormone-
sensitive PCa [3–5, 11–13]. The results obtained with
neoadjuvant ADT have implications for the use of [11C]
choline PET/CT in the initial staging of PCa, even though
this indication for the use of [11C]choline PET/CT remains
debated [13, 19, 20]. In patients undergoing [11C]choline
PET/CT during initial staging, the scan should be performed
before initiating ADT, or alternatively ADT should be
interrupted in good time before the scan.
Different considerations apply to patients who develop
biochemical failure during ADT, i.e. patients with hormone-
resistant PCa. In this group of patients there are currently
no available data derived from paired studies. However,
useful information has been obtained from cross-sectional
studies including a relatively large number of hormone-
sensitive and hormone-resistant patients in which the two
groups were contrasted either semiquantitatively or by
appropriate statistical analysis (logistic regression) [21, 22].
A first study carried out in 358 patients with PCa found
that [11C]choline PET/CT scans are more frequently
positive in hormone-resistant patients than in hormone-
sensitive patients (56% vs. 44%, respectively) [21]. This is
in contrast to the notion that ADT substantially impairs
[11C]choline uptake in hormone-resistant patients. More-
over, hormone resistance was a significant predictor of a
positive [11C]choline PET/CT scan in univariate analysis.
This finding could be attributed to the greater aggressive-
ness of the disease and/or to the greater prevalence of other
predictive factors (i.e. more advanced pathological stage,
higher PSA levels, etc.) in the group of hormone-resistant
patients with PCa. Similar findings were obtained by
Castellucci et al. in 102 patients with PSA levels below
1.5 ng/ml [22]. Other studies that have shown a positive
detection rate of the technique in both subgroups of
patients, consistently showed higher percentage values in
hormone-resistant patients than in hormone-sensitive
patients [21, 23–26]. Overall, these results suggest that in
patients who develop biochemical failure during ADT,
ADT itself does not significantly affect the uptake of [11C]
choline in sites of disease recurrence. On the contrary,
hormone-resistant patients who develop biochemical failure
are more likely to show a positive [11C]choline PET/CT
scan than hormone-sensitive patients [21, 22, 25].
Fuccio et al. also comment in the Discussion that on the
basis of their results “it may be suggested that the
withdrawal of ADT before execution of [11C]choline PET/
CT could increase the detection rate and the intensity of
choline uptake in metastatic lesions, therefore increasing
the sensitivity of the [11C]choline PET/CT scan” [3]. We
would like to comment on this statement. Although ADT
withdrawal in hormone-resistant patients could increase
[11C]choline uptake, the cross-sectional studies discussed
above [21–26] suggest that this effect is likely to be modest.
It is, however, of little importance if ADT withdrawal
induces a slight increase in [11C]choline uptake in some
metastatic lesions. As Fuccio et al. [3] imply, the real
question that needs to be addressed is whether ADT
withdrawal induces a significant increase in the positive
detection rate of the technique, i.e. whether it substantially
decreases the number of false-negative scans. A conclusive
answer to this question could be obtained only by an ad hoc
defined paired study. A suitable study design would require an
initial [11C]choline PET/CT scan at the time of biochemical
progression, then fast withdrawal of antiandrogenic drugs
and acquisition of a second [11C]choline PET/CT scan during
pharmacological wash-out. The two paired studies should be
performed with the shortest possible interval between them
to avoid any progression of the disease. Castration testoster-
one levels are reached over 2–4 weeks after ADT, with
variations depending on the drug used [1]. In the absence of
strong evidence for an inhibitory effect of ADT in patients
with hormone-resistant PCa, prolonged withdrawal of ADT
in oncological patients experiencing progression of disease
may be ethically questionable. Moreover, since 56% to 85%
of hormone-resistant patients would be expected to have a
positive [11C]choline/[18F]fluorocholine PET/CT scan [21,
23–26], systematic ADT withdrawal in all patients before
PET/CT would be useless in the majority.
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In summary, we feel that at the present time there is
insufficient evidence to support the withdrawal of ADT on a
regular basis before [11C]choline (or [18F]fluorocholine) PET/
CT scanning in patients with hormone-resistant PCa. In
addition to further ad hoc clinical data, a deeper understanding
of the biochemical mechanisms underlying the inhibition of
uptake of radiolabelled choline by ADT is required.
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